Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 1/2017

24.01.2017 | Overactive Bladder (U Lee, Section Editor)

Urinary Tract Infection Rates and Mechanisms After OnabotulinumtoxinA Bladder Injection: a Review

verfasst von: Daniel Hoffman, Kimberly L. Ferrante

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Intradetrusor onabotulinumtoxinA therapy has proven effective in decreasing episodes of urgency urinary incontinence and improving quality of life in patients with refractory idiopathic and neurogenic detrusor overactivity. While the definition and reporting of urinary tract infections as well as dosing of onabotulinumtoxin varied across trials, there was a demonstrated increased risk of developing a urinary tract infection with onabotulinumtoxinA injections when compared to placebo injection.

Recent Findings

Occurrence of urinary tract infections was found to persist through multiple treatment cycles, while the rates of catheterization seem to decrease with subsequent treatments.

Summary

While multiple theories exist, the current literature has not been able to elucidate the mechanism by which intradetrusor onabotulinumtoxinA injections increase the risk of urinary tract infections.
Literatur
1.
Abrams P et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.CrossRefPubMed
2.
Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology. 2002;60(5 Suppl 1):7–12. discussion 12.CrossRefPubMed
3.
Milsom I et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–6.CrossRefPubMed
4.
•• Nitti VW, et al. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol. 2016. Highlights the safety and efficacy of onabotulinumtoxinA over time and shows that the CIC rate decreases over time while infection rates remain stable.
5.
6.
7.
Flynn MK et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181(6):2608–15.CrossRefPubMedPubMedCentral
8.
Anger JT et al. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol. 2010;183(6):2258–64.CrossRefPubMedPubMedCentral
9.
Dmochowski R et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–22.CrossRefPubMed
10.
Sahai A et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology. 2010;75(3):552–8.CrossRefPubMed
11.
•• Rovner E, et al. Long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity who completed 4 years of treatment. J Urol. 2016. Highlights the safety and efficacy of onabotulinumtoxinA over time in the neurogenic population and shows that while the rate of self-catheterization decreases over time, UTI rates do not.
12.
Kennelly M, et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn. 2015.
13.
• Mouttalib S et al. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment. BJU Int. 2010;106(11):1677–80. Highlights importance of antimicrobial prophylaxis prior to onabotulinumtoxinA injection.CrossRefPubMed
14.
Manack A et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011;30(3):395–401.CrossRefPubMed
15.
Jahromi MS, Mure A, Gomez CS. UTIs in patients with neurogenic bladder. Curr Urol Rep. 2014;15(9):433.CrossRefPubMed
Metadaten
Titel
Urinary Tract Infection Rates and Mechanisms After OnabotulinumtoxinA Bladder Injection: a Review
verfasst von
Daniel Hoffman
Kimberly L. Ferrante
Publikationsdatum
24.01.2017
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 1/2017
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-017-0404-9

Weitere Artikel der Ausgabe 1/2017

Current Bladder Dysfunction Reports 1/2017 Zur Ausgabe

Stress Incontinence and Prolapse (R Dmochowski, Section Editor)

An Update on the Management of Neurogenic Bladder

Stress Incontinence and Prolapse (R Dmochowski, Section Editor)

The Evidence for Female Pelvic Medicine Interventions

Stress Incontinence and Prolapse (R Dmochowski, Section Editor)

Uterine Prolapse and Preservation Methods: a Literature Review

Stress Incontinence and Prolapse (R Dmochowski, Section Editor)

Sacral Neuromodulation for the Treatment of Pelvic Floor Disorders

Overactive Bladder (U Lee, Section Editor)

Resolution of Overactive Bladder After Mid-Urethral Sling Placement With Mixed Incontinence

Overactive Bladder (U Lee, Section Editor)

De Novo Overactive Bladder Symptoms After Sling Placement

Neu im Fachgebiet Urologie

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

22.04.2024 | Prostatakarzinom | Nachrichten

Stufenschema weist Prostatakarzinom zuverlässig nach

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Varikozelen bei Jugendlichen: Das Für und Wider der Operation
weitere anzeigen

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen